申请人:SANKYO COMPANY LIMITED
公开号:EP0799823A1
公开(公告)日:1997-10-08
Compounds of formula (I) and (II):
[in which R is hydrogen, halogen or alkyl; R1 is alkyl, amino or substituted amino; R2 is optionally substituted phenyl; R3 is hydrogen, halogen or optionally substituted alkyl; R4 is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, or aralkyl] have valuable analgesic, anti-inflammatory, anti-pyretic and anti-allergic activities and have the ability to inhibit the production of leukotrienes and to inhibit bone resorption. They are relatively free from the side effects which generally result from the administration of compounds having these kinds of activities.
式(I)和(II)化合物:
[其中 R 是氢、卤素或烷基;R1 是烷基、氨基或取代氨基;R2 是任选取代的苯基;R3 是氢、卤素或任选取代的烷基;R4 是氢、任选取代的烷基、环烷基、芳基或芳烷基]具有重要的镇痛、消炎、解热和抗过敏活性,并能抑制白三烯的生成和抑制骨吸收。它们相对来说没有副作用,而副作用通常是由服用具有此类活性的化合物引起的。